SCHEMBL822790

SCHEMBL822790

Cc1ccc(-c2ccc(Oc3ccccc3)cc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
LTA4H P09960 5/20 0.57
TSHR P16473 1/20 0.57
TEAD4 Q15561 1/20 0.54
ALDH1A1 P00352 2/20 0.52
MAPT P10636 2/20 0.52
POLB P06746 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
GSTP1 P09211 1/20 0.52
FFAR1 O14842 1/20 0.51
NR1H2 P55055 1/20 0.50
BAX Q07812 1/20 0.50
MAOA P21397 1/20 0.50
FFAR4 Q5NUL3 1/20 0.49
MAPK14 Q16539 1/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
LMNA P02545 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24322042 1.00 HTT (0.62) HTTSMN1; SMN2LTA4HTSHRTEAD4
SCHEMBL20419433 1.00 HTT (0.62) HTTSMN1; SMN2LTA4HTSHRTEAD4
SCHEMBL537243 0.95 HTT (0.57) HTTSMN1; SMN2LTA4HTSHRTEAD4
SCHEMBL16361074 0.95 HTT (0.57) HTTSMN1; SMN2LTA4HTSHRTEAD4
SCHEMBL2058591 0.95 HTT (0.57) HTTSMN1; SMN2LTA4HTSHRTEAD4
Diphenylether SCHEMBL9751563 0.95 LTA4H (0.57) HTTSMN1; SMN2LTA4HTSHRTEAD4
Biphenyl SCHEMBL312988 0.93 HTT (0.59) HTTSMN1; SMN2LTA4HTSHRTEAD4
SCHEMBL12355 0.93 HTT (0.69) HTTSMN1; SMN2LTA4HTSHRTEAD4
SCHEMBL425356 0.93 HTT (0.69) HTTSMN1; SMN2LTA4HTSHRTEAD4
SCHEMBL17081753 0.93 HTT (0.69) HTTSMN1; SMN2LTA4HTSHRTEAD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190264045-A1 POLY-(ARYL-ETHER-KETONE) (PAEK) COMPOSITION WITH A LOW CONTENT OF VOLATILE COMPOUNDS AND USE OF SAME IN A SINTERING METHOD ARKEMA FRANCE (FR) 2019-08-29 US disclosed
US-RE47556-E1 Optical element compound, optical material, and optical element CANON KABUSHIKI KAISHA (JP) 2019-08-06 US disclosed
US-8829230-B2 Optical element compound, optical material, and optical element CANON KABUSHIKI KAISHA (JP) 2014-09-09 US disclosed
US-20140031582-A1 OPTICAL ELEMENT COMPOUND, OPTICAL MATERIAL, AND OPTICAL ELEMENT CANON KABUSHIKI KAISHA (JP) 2014-01-30 US disclosed
US-8569541-B2 Optical element compound, optical material, and optical element CANON KABUSHIKI KAISHA (JP) 2013-10-29 US disclosed
US-20110288330-A1 OPTICAL ELEMENT COMPOUND, OPTICAL MATERIAL, AND OPTICAL ELEMENT CANON KABUSHIKI KAISHA (JP) 2011-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288330-A1 OPTICAL ELEMENT COMPOUND, OPTICAL MATERIAL, AND OPTICAL ELEMENT CENPE, AXIN2, CCNE2 HTT 3535/4885SMN1; SMN2 1377/4885LTA4H 2503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.